Cue Biopharma (CUE) Current Assets (2017 - 2025)

Cue Biopharma has disclosed Current Assets across 9 years of filings, most recently posting $37.0 million for Q4 2025.

• Current Assets for Q4 2025 came in at $37.0 million, up 47.12% year-over-year; the trailing twelve-month figure through Dec 2025 was $37.0 million (up 47.12% YoY), and the FY2025 annual result was $37.0 million, up 47.12% from the prior year.
• Current Assets came in at $37.0 million for Q4 2025 at Cue Biopharma, up from $25.8 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $79.7 million in Q2 2021 to a low of $15.9 million in Q1 2025.
• The 5-year median for Current Assets is $59.2 million (2023), against an average of $53.4 million.
• Across the five-year window, Current Assets surged 51.21% in 2021 and sank 64.34% in 2025, its largest moves.
• Cue Biopharma's Current Assets stood at $68.5 million in 2021, then rose by 12.73% to $77.2 million in 2022, then tumbled by 33.34% to $51.5 million in 2023, then slumped by 51.14% to $25.1 million in 2024, then soared by 47.12% to $37.0 million in 2025.
• The last three Current Assets figures came in at $37.0 million (Q4 2025), $25.8 million (Q3 2025), and $30.8 million (Q2 2025), per Business Quant data.